Clinical Trials
7 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05012397 2024-10-17
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 2 Terminated
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated